MedPacto CEO Kim Sung-jin Appointed Adjunct Professor at Yale School of Medicine, USA

MedPacto announced on the 6th that CEO Kim Sung-jin, a world-renowned tumor biology expert, has been appointed as a Professor Adjunct at Yale University School of Medicine in the United States.

While there have been cases of Yale professors serving as research advisors for domestic pharmaceutical and biotech companies, this is the first time a CEO of a Korean pharmaceutical and biotech company has been appointed as a Professor Adjunct at Yale University School of Medicine.

CEO Kim Sung-jin plans to establish various collaborative relationships with the Yale medical team regarding the clinical trials of innovative new drug candidates currently being developed by MedPacto. Additionally, he will promote the development of innovative cancer treatments through joint research with world-class cancer specialists affiliated with Yale University.

CEO Kim Sung-jin was the first to identify and publish in Nature that the loss and mutation of the TGF-β (transforming growth factor beta) receptor gene play a decisive role in the carcinogenesis process of major human cancers. He was the first Korean and the fifth person worldwide to decode the human personal genome map, and has published over 320 papers, including the decoding of the Korean gastric cancer genome.

From 1987, Kim served as a tenured senior researcher at the National Cancer Institute (NCI) under the U.S. National Institutes of Health (NIH) for 20 years. He returned to Korea in 2007 and held positions such as Director of the Gachon University Lee Gil-ye Cancer and Diabetes Research Institute, Director of the CHA University Cancer Research Institute, and Director of the Precision Medicine Center at Seoul National University’s Next-Generation Convergence Technology Research Institute. Currently, he is the CEO of MedPacto and Director of the Gilo Foundation Research Institute, dedicating himself to basic research on various diseases.

A MedPacto official stated, "The research and development areas, including the development and clinical trials of MedPacto’s pipeline overseen by CEO Kim Sung-jin, will proceed without any setbacks," and added, "We expect that collaborative research with Yale University will greatly aid MedPacto’s new drug development."